Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer.
An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP, and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.
Kusumoto
H
H
Cancer Centre of Kyushu University Hospital, Fukuoka, Japan.
Maehara
Y
Y
Kusumoto
T
T
Anai
H
H
Akazawa
K
K
Sugimachi
K
K
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D011184:Postoperative Period; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D013385:Succinate Dehydrogenase